EUVIMEDEUVIMED entdecken
Open Access · CC BY-ND 4.0

Anthracycline-Induced Cardiomyopathy in Breast Cancer Patients in Oman: A retrospective study

Anthrazyklin-induzierte Kardiomyopathie bei Brustkrebspatientinnen in Oman: retrospektive Studie

Hussain A Al-Lawati, Khalid Al Baimani, Mohammed N Al Rawahi

Sultan Qaboos University Medical Journal · 08.09.2025 · 25 (1) · 839-846

DOI: 10.18295/2075-0528.2891 ↗

Auf einen Blick

Bei 385 Brustkrebspatientinnen in Oman entwickelte sich nach Anthrazyklin-Exposition bei 39 eine Kardiomyopathie (10,1 %).

Fragestellung

Wie hoch ist die Prävalenz der anthrazyklininduzierten Kardiomyopathie bei Brustkrebspatientinnen in Oman?

Methode

Retrospektive Studie mit Brustkrebspatientinnen, die zwischen September 2008 und Dezember 2020 ausschließlich anthrazyklinbasierte Chemotherapie erhielten.

Ergebnisse

385 Patientinnen; 39 (10,1 %) entwickelten eine Kardiomyopathie. Die mittlere kumulative Doxorubicin-Dosis betrug 239 mg/m2. In der Univarianzanalyse waren Risikofaktoren und Trastuzumab-Exposition mit höherem Risiko assoziiert.

Schlussfolgerung der Autor:innen

Die anthrazyklininduzierte Kardiomyopathie war mit verschiedenen kardiovaskulären Risikofaktoren sowie mit Trastuzumab-Exposition verbunden. Weitere Studien werden empfohlen.

Kernaussagen

  • Kardiomyopathie bei 39 von 385 Patientinnen (10,1 %)
  • Mittlere kumulative Doxorubicin-Dosis: 239 mg/m2
  • Trastuzumab-Exposition war univariat mit höherem Risiko assoziiert

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Sultan Qaboos University Medical Journal, online erschienen am 08.09.2025. Verfasst von Hussain A Al-Lawati und 2 weiteren Autor:innen. Beteiligte Einrichtung: Intensive Care Unit, Royal Hospital, Muscat, Oman. Hauptthemen laut MEDLINE: Breast Neoplasms, Anthracyclines, Cardiomyopathies. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-ND 4.0).

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Anthracyclines are widely used in the treatment of breast cancer. One of the known adverse effects of anthracyclines is anthracycline-induced cardiomyopathy. Studies done worldwide showed that the prevalence of chemotherapy-induced cardiomyopathy is approximately 9%. However, studies evaluating this complication prevalence, risk factors and cumulative dose are lacking in Oman. This study aimed to investigate the prevalence of anthracycline-induced cardiomyopathy among breast cancer patients in Oman.

Methods

This retrospective study included all breast cancer patients who received anthracycline-based chemotherapy exclusively between September 2008 and December 2020 at Sultan Qaboos University Hospital in Muscat. Patients with partial treatment, coexisting heart failure and who did not receive anthracycline as part of the chemotherapy regimen were excluded. Chemotherapy-induced cardiomyopathy was defined as a drop of left ventricular ejection fraction >10% from the patient’s baseline during or after receiving anthracycline-based chemotherapy.

Results

A total of 385 patients were included in this study of which 39 (10.1%) developed cardiomyopathy after exposure to anthracyclines. The mean cumulative dose of doxorubicin among these patients was 239 mg/m2 (epirubicin was converted to doxorubicin equivalent dose). Univariate analysis showed that the risk of anthracycline-induced cardiomyopathy was influenced by cardiovascular risk factors such as hypertension (33.3%), diabetes (25.6%), dyslipidaemia (20.5%) and previous cardiovascular medications use (10.3%). Trastuzumab exposure significantly correlated with an increased risk of developing cardiomyopathy (P < 0.001). However, multivariate analysis did not show any significant association.

Conclusions

Anthracycline-induced cardiomyopathy was influenced by various cardiovascular risk factors as well as trastuzumab exposure. Further studies are recommended to investigate the prevention and management of anthracycline-induced cardiomyopathy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsAnthracyclinesCardiomyopathiesHumansRetrospective StudiesOmanFemaleMiddle AgedAdultRisk FactorsPrevalenceAged

Stichwörter der Autor:innen

Adverse EffectsAnthracyclinesBreast NeoplasmsCardiomyopathiesDoxorubicinDrug TherapyOmanToxicity

Substanzen

Anthracyclines

Autor:innen und Institutionen

  • Intensive Care Unit, Royal Hospital, Muscat, Oman.
  • Medical Oncology Department, Sultan Qaboos Comprehensive Cancer Care & Research Centre, University Medical City, Muscat, Oman.
  • Cardiology Department, Sultan Qaboos University Hospital, University Medical City, Muscat, Oman.

Zitieren

APA

Al-Lawati, H. A., Al Baimani, K., & Al Rawahi, M. N. (2025). Anthracycline-Induced Cardiomyopathy in Breast Cancer Patients in Oman: A retrospective study. Sultan Qaboos University Medical Journal, 25(1), 839-846. https://doi.org/10.18295/2075-0528.2891

Vancouver

Al-Lawati HA, Al Baimani K, Al Rawahi MN. Anthracycline-Induced Cardiomyopathy in Breast Cancer Patients in Oman: A retrospective study. Sultan Qaboos University Medical Journal. 2025;25(1):839-846. doi:10.18295/2075-0528.2891

BibTeX
@article{AlLawati2025,
  author = {Al-Lawati, Hussain A and Al Baimani, Khalid and Al Rawahi, Mohammed N},
  title = {Anthracycline-Induced Cardiomyopathy in Breast Cancer Patients in Oman: A retrospective study},
  journal = {Sultan Qaboos University Medical Journal},
  year = {2025},
  volume = {25},
  number = {1},
  pages = {839--846},
  doi = {10.18295/2075-0528.2891}
}
Kostenlos starten →